Алоглиптин в лечении сахарного диабета 2 типа: доказательная база для клинического применения


DOI: https://dx.doi.org/10.18565/pharmateca.2018.11.17-24

Е.В. Бирюкова

Московский государственный медико-стоматологический университет им. А.И. Евдокимова, Москва, Россия
Сахарный диабет 2 типа – тяжелое заболевание, связанное с развитием тяжелых осложнений. Обсуждаются современные подходы к лечению, включающие применение лекарственных средств, действие которых основано на «эффектах инкретинов», механизм действия ингибиторов дипептидилпептидазы-4. Представлены результаты клинических исследований эффективности и безопасности алоглиптина.
Ключевые слова: сахарный диабет 2 типа, сердечно-сосудистые заболевания, сахароснижающая терапия, ингибиторы дипептидилпептидазы-4, алоглиптин

Литература


1. Papatheodorou K., Papanas N., Banach M., et al. Complications of Diabetes. J. Diab. Res. 2016;2016:6989453.

2. Vilsboll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetol. 2004;47:357–66.

3. Pratley R.E., Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin. 2007;23:919–31.

4. Aroda V.R., Henry R.R., Han J., et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review. Clin. Ther. 2012;34(6):1247–58.

5. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diab. Obes. Metab. 2011;13: 7–18.

6. Deacon C.F., Lebovitz H.E. Comparative review ofdipeptidyl peptidase-4 inhibitors and sulpho-nylureas. Diab. Obes. Metab. 2016;18:333–47.

7. Johns E., McKay G., Fisher M. Dipeptidyl peptidase-4 (DPP-4) inhibitors. Br. J. Cardiol. 2017;24:(1). Doi:10.5837/bjc.2017.001.

8. Lim S.W., Jin J. Z., Jin L., et al. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation. Kor. J. Intern. Med. 2015;30(6):759–70.

9. Godinho R., Mega C., Teixeira-de-Lemos E., et al. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A «Me Too» or «the Special One» Antidiabetic Class? J. Diab. Res. 2015;2015:1–28. Doi: 10.1155/2015/806979.

10. Gooßen K, G.räber S. Longer term safety of dipeptidyl peptidase-4 in- hibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diab. Obes. Metab. 2012;14:1061–72.

11. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, 8-й выпуск. М., 2017.

12. Baetta R., Corsini A. Pharmacology of dipeptidylpeptidase-4 inhibitors. Drugs 2011;71(11):1441–67.

13. Saisho Y. Alogliptin benzoate for management of type 2 diabetes. Vasc. Health Risk Management. 2015:11:229–43.

14. Dineen L., Law C., Scher R. Alogliptin (Nesina) for Adults With Type-2 Diabetes. P.T. 2014;39(3):186, 192–8, 202.

15. Seino Y., Fujita T., Hiroi S., et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr. Med. Res. Opin. 2011;27:1781–92.

16. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, place-bo-controlled study. Diab. Care. 2008;31:2315–17.

17. Capuano A Sportiello L., Maiorino M.I., Rossi F., et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Des. Devel. Ther. 2013;7:989–1001.

18. Seino Y., Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp. Opin. Pharmacother. 2014;15(6):851–63.

19. Liu Y., Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diab. Obes. Metab. 2014;16(2):111–17. doi: 10.1111/dom.12128.

20. ChonS., GautierJ-F. An Update on the effect of incretin-based therapies on β-cell function and mass. Diab. Metab. J. 2016;40:99–114.

21. Wu D., Li L., Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis Diab. Obes. Metab. 2014;16(1):30–7. Doi: 10.1111/dom.12174. Epub 2013 Jul 16.

22. DeFronzo R.A., Hissa M.N., Garber A.J., et al.; Saxagliptin 014 Study Group. The Efficacy and safety of alogliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diab. Care. 2009;32(9):1649–55.

23. Stahn A., Pistrosch F., Ganz X., et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diab. Care. 2014;37:516–20.

24. Del Prato S., et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diab. Obes. Metab. 2014;16(12):1239–46.

25. Khaled A.A., Sekaran M., Ikram S.I. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomed. Res. 2010;21(2):147–55.

26. Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diab. 2015;6(13):1246–58.

27. Zoungas S., Patel A. Cardiovascular outcomes intype 2 diabetes: the impact of preventative thera-pies. Ann. N. Y. Acad. Sci. 2010;1212(1):29–40.

28. Low Wang C.C., Hess C.N., Goldfine A.B. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation. 2016;133:2459–502. Doi:10.1161/CIRCULATIONAHA.116.022194.

29. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013;369:1327–35.

30. Khan M., Deaton C., Rutter M., et al. Incretins as a novel therapeutic strategy in patients with diabetes andheart failure. Heart Fail. Rev. 2013;18:141–48.

31. Chrysant S.G., Chrysant G.S. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am. J. Cardiol. 2012;109(11):1681–85.

32. Avogaro A., Fadini G.P. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.Br. J. Clin. Pharmacol. 2018;84(8):1686–95. Doi: 10.1111/bcp.13611.

33. Lund A. On the role of the gut in diabetic hyperglucagonaemia. Dan. Med. J. 2017;64(4):pii:B5340.

34. Pratley R.E., McCall T., Fleck P.R., et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J. Am. Geriatr. Soc. 2009;57(11):2011–19.

35. Rosenstock J., Wilson C., Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diab. Obes. Metab. 2013;15(10):906–14. Doi: 10.1111/dom.12102.

36. Bron M., Wilson C., Fleck P. A post hoc analysis of HbA1c, hypoglycemia, and weight change outcomes with alogliptin vs glipizide in older patients with type 2 diabetes. Diab. Ther. 2014;5:521–34.

37. Moritoh Y., Takeuchi K., Asakawa T., et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008;588(2–3):325–32.

38. Kawashima S., Matsuoka T.A., Kaneto H., et al. Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice. Biochem Biophys Res Commun. 2011;404(1):534–40.

39. Zhang X., Wang Z., Huang Y., Wang J. Effects of chronic administration of alogliptin on the development of diabetes and beta-cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metab. 2011;13(4):337–47.

40. Yin H., Park S.Y., Wang X.J., et al. Enhancing pancreatic beta-cell regeneration in vivo with pioglitazone and alogliptin. PLoS One. 2013;8(6):e65777.


Об авторах / Для корреспонденции


Автор для связи: Е.В. Бирюкова, д.м.н., проф., кафедра эндокринологии и диабетологии, МГМСУ им. А.И. Евдокимова, Москва, Россия;
e-mail: lena@obsudim.ru; ORCID: https://orcid.org/0000-0001-9007-4123
Адрес: 127473, Россия, Москва, ул. Делегатская, 20, стр. 1


Бионика Медиа